Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 3 studies | 29% ± 13% |
Insufficient scRNA-seq data for expression of DAGLA at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 100% | 866.46 | 963 / 966 | 98% | 12.76 | 517 / 527 |
brain | 98% | 2059.08 | 2601 / 2642 | 99% | 23.60 | 697 / 705 |
stomach | 97% | 458.99 | 348 / 359 | 97% | 13.26 | 276 / 286 |
pancreas | 100% | 896.45 | 328 / 328 | 89% | 6.11 | 159 / 178 |
esophagus | 98% | 718.47 | 1416 / 1445 | 87% | 10.27 | 160 / 183 |
breast | 100% | 838.76 | 457 / 459 | 85% | 5.55 | 948 / 1118 |
prostate | 98% | 774.14 | 241 / 245 | 85% | 4.87 | 426 / 502 |
lung | 99% | 626.43 | 571 / 578 | 80% | 5.56 | 924 / 1155 |
adrenal gland | 94% | 443.49 | 243 / 258 | 79% | 5.79 | 181 / 230 |
thymus | 97% | 419.08 | 634 / 653 | 72% | 3.32 | 437 / 605 |
kidney | 89% | 374.58 | 79 / 89 | 75% | 3.48 | 679 / 901 |
skin | 71% | 284.22 | 1280 / 1809 | 89% | 14.83 | 422 / 472 |
uterus | 98% | 659.26 | 167 / 170 | 58% | 3.36 | 266 / 459 |
bladder | 81% | 216.86 | 17 / 21 | 61% | 4.99 | 309 / 504 |
ovary | 59% | 185.17 | 107 / 180 | 82% | 5.54 | 354 / 430 |
eye | 0% | 0 | 0 / 0 | 100% | 8.02 | 80 / 80 |
adipose | 99% | 538.85 | 1187 / 1204 | 0% | 0 | 0 / 0 |
spleen | 98% | 526.51 | 236 / 241 | 0% | 0 | 0 / 0 |
heart | 92% | 467.47 | 795 / 861 | 0% | 0 | 0 / 0 |
muscle | 88% | 536.10 | 709 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 60% | 3.20 | 27 / 45 |
liver | 12% | 48.68 | 27 / 226 | 45% | 2.40 | 181 / 406 |
blood vessel | 51% | 147.18 | 676 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 21% | 0.69 | 6 / 29 |
peripheral blood | 5% | 10.62 | 47 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006640 | Biological process | monoacylglycerol biosynthetic process |
GO_0098921 | Biological process | retrograde trans-synaptic signaling by endocannabinoid |
GO_0150077 | Biological process | regulation of neuroinflammatory response |
GO_0007216 | Biological process | G protein-coupled glutamate receptor signaling pathway |
GO_0046340 | Biological process | diacylglycerol catabolic process |
GO_1901696 | Biological process | cannabinoid biosynthetic process |
GO_0019369 | Biological process | arachidonic acid metabolic process |
GO_0007405 | Biological process | neuroblast proliferation |
GO_0098839 | Cellular component | postsynaptic density membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0031901 | Cellular component | early endosome membrane |
GO_0043196 | Cellular component | varicosity |
GO_0032591 | Cellular component | dendritic spine membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0045211 | Cellular component | postsynaptic membrane |
GO_0032590 | Cellular component | dendrite membrane |
GO_0004465 | Molecular function | lipoprotein lipase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0047372 | Molecular function | acylglycerol lipase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | DAGLA |
Protein name | Diacylglycerol lipase-alpha (DAGL-alpha) (DGL-alpha) (EC 3.1.1.116) (Neural stem cell-derived dendrite regulator) (Sn1-specific diacylglycerol lipase alpha) Diacylglycerol lipase alpha |
Synonyms | KIAA0659 NSDDR C11orf11 |
Description | FUNCTION: Serine hydrolase that hydrolyzes arachidonic acid-esterified diacylglycerols (DAGs) to produce the principal endocannabinoid, 2-arachidonoylglycerol (2-AG) . Preferentially hydrolyzes sn-1 fatty acids from diacylglycerols (DAG) that contain arachidonic acid (AA) esterified at the sn-2 position to biosynthesize 2-AG . Has negligible activity against other lipids including monoacylglycerols and phospholipids . Plays a key role in regulating 2-AG signaling in the central nervous system (CNS). Regulates 2-AG involved in retrograde suppression at central synapses. Supports axonal growth during development and adult neurogenesis. Plays a role for eCB signaling in the physiological regulation of anxiety and depressive behaviors. Regulates also neuroinflammatory responses in the brain, in particular, LPS-induced microglial activation (By similarity). . |
Accessions | ENST00000540717.1 ENST00000257215.10 F5GY58 Q9Y4D2 |